METHSUXIMIDE
Methsuximide is an antiepileptic medication indicated for the control of absence (petit mal) seizures that are refractory to other treatments. It is a succinimide derivative typically reserved for patients who have not achieved adequate seizure control with first-line therapies.
How METHSUXIMIDE Works
Methsuximide exerts its therapeutic effect by suppressing the paroxysmal three-cycle-per-second spike-and-wave activity characteristic of absence seizures. At the cellular level, it acts by inhibiting T-type voltage-gated calcium channels in thalamic neurons. This inhibition reduces the thalamocortical oscillations that trigger absence seizures. Methsuximide is rapidly metabolized to its active metabolite, N-desmethylmethsuximide, which also contributes significantly to its anticonvulsant activity.
Details
- Status
- Prescription
- First Approved
- 2023-05-01
- Routes
- ORAL
- Dosage Forms
- CAPSULE
METHSUXIMIDE Approval History
What METHSUXIMIDE Treats
1 indicationsMETHSUXIMIDE is approved for 1 conditions since its original approval in 2023. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Seizures
Drugs Similar to METHSUXIMIDE
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
METHSUXIMIDE FDA Label Details
ProIndications & Usage
INDICATIONS & USAGE Methsuximide is indicated for the control of absence (petit mal) seizures that are refractory to other drugs.
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.